Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“Our collaborative effort to characterize MET kinase domain mutations as novel and targetable alterations in NSCLC and other cancer types is out in Cancer Discovery AACR Journals. In this study led by our stellar scientists Federica Pecci and Shesiru Nakazawa we identified that activating MET TKD mutations occur in multiple malignancies and can confer clinical sensitivity to currently available MET inhibitors. This study highlights the importance of performing comprehensive genomic tumor profiling to detect rare but targetable drivers.”